These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21910805)

  • 21. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss).
    Kaufman KD; Rotonda J; Shah AK; Meehan AG
    Eur J Dermatol; 2008; 18(4):400-6. PubMed ID: 18573712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
    Wolff H; Kunte C
    MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
    Finasteride Male Pattern Hair Loss Study Group
    Eur J Dermatol; 2002; 12(1):38-49. PubMed ID: 11809594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
    Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
    Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
    Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
    PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgenetic alopecia: an update.
    Kaliyadan F; Nambiar A; Vijayaraghavan S
    Indian J Dermatol Venereol Leprol; 2013; 79(5):613-25. PubMed ID: 23974579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.
    Olsen EA; Whiting DA; Savin R; Rodgers A; Johnson-Levonas AO; Round E; Rotonda J; Kaufman KD;
    J Am Acad Dermatol; 2012 Sep; 67(3):379-86. PubMed ID: 22325459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
    Price VH; Menefee E; Sanchez M; Ruane P; Kaufman KD
    J Am Acad Dermatol; 2002 Apr; 46(4):517-23. PubMed ID: 11907500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ; Dhurat RS
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature.
    Boychenko O; Bernstein RM; Schweiger ES
    Cutis; 2012 Aug; 90(2):73-6. PubMed ID: 22988650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics.
    Keene S; Goren A
    Dermatol Ther; 2011; 24(2):296-300. PubMed ID: 21410621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Finasteride induced depression: a prospective study.
    Rahimi-Ardabili B; Pourandarjani R; Habibollahi P; Mualeki A
    BMC Clin Pharmacol; 2006 Oct; 6():7. PubMed ID: 17026771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.